Naloxone Dosing for Opioid Overdose in Adults
For suspected opioid overdose in adults, administer an initial dose of 0.4-2 mg IV/IM/SC, titrating to restore adequate respiratory function—not full consciousness—with repeat doses every 2-3 minutes as needed. 1, 2
Initial Dosing Strategy
The 2023 American Heart Association guidelines provide clear dosing parameters for opioid overdose reversal 1:
- Initial dose: 0.2-2 mg IV/IO/IM 1
- Intranasal route: 2-4 mg, repeated every 2-3 minutes as needed 1
- Titrate to reversal of respiratory depression and restoration of protective airway reflexes—not to full alertness 1, 2
The FDA-approved dosing confirms this range, specifying 0.4-2 mg as the initial dose, with repeat administration at 2-3 minute intervals if needed 2. If no response occurs after 10 mg total, question the diagnosis of opioid toxicity 2.
Route-Specific Considerations
Intravenous administration provides the most rapid onset and is recommended in emergency situations 2. However, intramuscular or subcutaneous routes are acceptable when IV access is unavailable 2.
For intranasal administration, higher-concentration formulations (2 mg/mL) demonstrate similar efficacy to intramuscular naloxone, while lower-concentration formulations (2 mg/5 mL) may be less effective 3. The intranasal route has approximately 50% bioavailability with a mean time to maximum concentration of 15-30 minutes, likely slower than intramuscular administration 4.
Critical Titration Principles
The goal is respiratory restoration, not reversal of analgesia or induction of full consciousness 1, 2. This approach minimizes precipitated withdrawal while ensuring adequate ventilation.
- Start with lower doses (0.4 mg) in opioid-dependent patients to avoid precipitated withdrawal 5
- Increase incrementally based on respiratory response 2
- Avoid excessive dosing that may cause acute opioid withdrawal syndrome, hypertension, pulmonary edema, or cardiovascular stress 2, 5
Maintenance and Monitoring
Naloxone's duration of action (approximately 60-120 minutes) is often shorter than many opioids, particularly long-acting formulations and fentanyl 4. This necessitates:
- Continuous surveillance after initial reversal 2
- Maintenance infusion of two-thirds the waking dose per hour for sustained effect 1
- Preparation for repeat dosing as respiratory depression may recur 2, 4
For IV infusion, dilute 2 mg naloxone in 500 mL normal saline or 5% dextrose (concentration 0.004 mg/mL), using within 24 hours 2.
Special Circumstances
Fentanyl and synthetic opioid overdoses likely require higher naloxone doses than traditional opioids like heroin 4, 6. The initial 0.4-0.8 mg dose typically sufficient for heroin may be inadequate for fentanyl 4.
In combined opioid-benzodiazepine overdoses, administer naloxone first before considering other antidotes like flumazenil 1. This is particularly critical given the prevalence of opioid-adulterated illicit drugs 1.
Common Pitfalls
- Administering excessive doses: This precipitates severe withdrawal, agitation, hypertension, and cardiovascular complications without improving respiratory outcomes 2, 5
- Single-dose administration without monitoring: Naloxone's short half-life means respiratory depression frequently recurs, particularly with long-acting opioids or fentanyl 4
- Delaying naloxone in polypharmacy overdoses: When opioid involvement is suspected, naloxone should not be withheld pending definitive diagnosis 1
- Using inadequate doses for synthetic opioids: Standard heroin-based dosing may be insufficient for fentanyl overdoses 4
Access and Distribution
All individuals with opioid use disorder should have access to take-home naloxone, with at least two doses available for layperson administration 4, 6. Community-wide naloxone distribution has been associated with 25-46% lower opioid overdose rates 6.